Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases

Yusuke Kubo; Masanobu Ohishi; Yasuharu Nakashima; Ken Okazaki; Jun-Ichi Fukushi; Akiko Oyamada; Yukihide Iwamoto

Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases

Yusuke Kubo, Masanobu Ohishi, Yasuharu Nakashima, Ken Okazaki, Jun-Ichi Fukushi, Akiko Oyamada, Yukihide Iwamoto

Research output: Contribution to journal › Article › peer-review

Abstract

PURPOSE: Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.

MATERIALS AND METHODS: We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.

RESULTS: After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.

CONCLUSIONS: Our results indicate that IFX is efficacious and safe for AS in Japanese patients.

Original language	English
Pages (from-to)	316-322
Number of pages	7
Journal	Fukuoka igaku zasshi = Hukuoka acta medica
Volume	106
Issue number	12
Publication status	Published - Dec 1 2015

All Science Journal Classification (ASJC) codes

Medicine(all)

Cite this

@article{06fa6989f4b04f92ac0642f26e771638,

title = "Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases",

abstract = "PURPOSE: Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.MATERIALS AND METHODS: We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.RESULTS: After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.CONCLUSIONS: Our results indicate that IFX is efficacious and safe for AS in Japanese patients.",

author = "Yusuke Kubo and Masanobu Ohishi and Yasuharu Nakashima and Ken Okazaki and Jun-Ichi Fukushi and Akiko Oyamada and Yukihide Iwamoto",

year = "2015",

month = dec,

day = "1",

language = "English",

volume = "106",

pages = "316--322",

journal = "Fukuoka Acta Medica",

issn = "0016-254X",

publisher = "福岡医学会",

number = "12",

}

TY - JOUR

T1 - Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients

T2 - A Retrospective Study of 11 Cases

AU - Kubo, Yusuke

AU - Ohishi, Masanobu

AU - Nakashima, Yasuharu

AU - Okazaki, Ken

AU - Fukushi, Jun-Ichi

AU - Oyamada, Akiko

AU - Iwamoto, Yukihide

PY - 2015/12/1

Y1 - 2015/12/1

N2 - PURPOSE: Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.MATERIALS AND METHODS: We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.RESULTS: After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.CONCLUSIONS: Our results indicate that IFX is efficacious and safe for AS in Japanese patients.

AB - PURPOSE: Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.MATERIALS AND METHODS: We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.RESULTS: After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.CONCLUSIONS: Our results indicate that IFX is efficacious and safe for AS in Japanese patients.

UR - http://www.scopus.com/inward/record.url?scp=84982797700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982797700&partnerID=8YFLogxK

M3 - Article

C2 - 27159947

AN - SCOPUS:84982797700

SN - 0016-254X

VL - 106

SP - 316

EP - 322

JO - Fukuoka Acta Medica

JF - Fukuoka Acta Medica

IS - 12

ER -

Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this